|
Profile
|
Delegates :
Yoshikazu Nakamura |
|
Incorporated :
August 1 , 2003 |
Paid in Capital :
3261 Million yen |
Employees :
20 人 |
Address :
Shirokanedai Usui Build. Minato-ku. Shirokanedai 3-16-13 TOKYO
〒108-0071
|
TEL/FAX :
81-3-3440-3303 / 81-3-3440-3729 |
URL:
https://www.ribomic.com/eng/index.php |
Attachment :
|
Mission/Background :
RIBOMIC Inc. is a biopharmaceutical venture company based in Tokyo. The RiboART System can be applied to develop variety of aptamer pharmaceuticals. We aim to provide new drugs for a wide range of Unmet Medical Needs, including ophthalmic disorders, pain, fibrosis, and bone diseases.
subsidiary: RIBOMIC USA Inc. 2120 University Ave,Berkeley,CA 94704 USA CEO Yusuf Ali |
Technology & Business
|
The Ribomic Aptamer Refined Therapeutics (RiboART) system is the core of RIBOMIC drug discovery technology. Overall, it consists of technology, expertise, and experience in aptamer drug discovery and constitutes a variety of platforms that underlie new drug discoveries. By applying the RiboART system, it is possible to discover various new drugs essentially applicable to any target proteins, and not limited to one disease. Aptamer therapeutics has the following advantages over antibody drugs:Higher binding affinity to target proteins, Fewer limitations as to targets, Easier chemical modification, Production by chemical synthesis, and Lower antigenicity.
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
RBM-007
|
Phase1/2
|
anti FGF2 aptamer for age-related degeneration(AMD)
|
to start phase2 clinical trial, to license
|
RBM-007
|
Preclinical
|
anti FGF2 aptamer for Achondroplasia (ACH)
|
to start clinical study, to license
|
RBM-003
|
Preclinical
|
anti Cymase aptamer for Heart Failure
|
to start clicical study, to license
|
RBM-010
|
Preclinical
|
anti ADAMTS5 aptamer for osteoarthritis(OA)
|
to start clinical study, to license
|
IgG aptamer (RBM-101)
|
Service/Marketing
|
Affinity purification of human IgG and Fc-fusion proteins
|
to license
|
Highlights
|
2019.6 RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration 2019.1 Entered into a cooperative research agreement with Vitamin C60 BioResearch Corporation 2018.12 THE PRITZKER NEUROPSYCHIATRIC DISORDERS RESEARCH CONSORTIUM SIGNS A MATERIAL TRANSFER AGREEMENT WITH RIBOMIC INC. 2018.9 RIBOMIC’s Joint Project Selected for the CREST Program
|
Alliance strategy
|
to license in-house products including RBM-007 (anti FGF2 aptamer) . to collaborate with pharmaceutical company, diagnostics company, and cosmetics company using our aptamer discovery technology.
|
|
|